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Summary Previous work has implicated putative tumour-suppressor (ts) genes at 6q27 and a broad region at
6pl2-q23. Here we report the results of a coded, randomised study of allelic imbalance at 12 loci on 6q on 40
pairs of coded tumour-blood pairs from patients with ovarian tumours. Our results provide clear evidence for
the involvement of different regions of 6q in tumours of different histological subtypes. The involvement in
serous tumours of a ts gene at the distal site is confirmed. However, proximal 6q presents a complex picture,
with possibly three further ts genes: one at 6q21-23.3 involved at high frequency in benign and endometrioid
tumours, another at 6ql4-ql5, also involved in endometrioid tumours, and a third suggested by a smallest
region of deletion at 6ql6.3-q21, between D6S275 and D6S300, that appears to be involved in early stage
tumours. These observations point the way to a statistical study of the involvement of 6q in tumours of
different histological type and staging performed on larger cohorts of samples.
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Tumour progression involves the activation of oncogenes and
the loss of tumour suppressors. Clues to the location of
tumour-suppressor (ts) genes come from observed non-
random chromosome deletions that may indicate loss of a
wild-type allele allowing expression of a recessive mutated
form ofthe tumour-suppressor gene on the other homologue,
a molecular version of Knudsen's two-hit hypothesis for
cancer induction (Knudsen, 1971). In retinoblastoma, which
provided support for the two-hit hypothesis, alterations in
the RBI gene alone are sufficient to produce tumours. How-
ever, it is now clear that for many other types of tumours,
including ovarian carcinomas, malignancy is the result of
events occurring in multiple genes (Fearon and Vogelstein,
1990; Dodson et al., 1993). The elucidation of these events in
ovarian cancer is still at an early stage, but the results we
report here highlight the involvement of at least two, possibly
four, ts genes on the long arm of chromosome 6.
Frequent non-random deletions of chromosome 6q have
been observed in primary ovarian tumours, both cytogene-
tically (Pejovic et al., 1992; Thompson et al., 1994) and at the
molecular level by loss of constitutional heterozygosity
(LOH; Ehlen and Dubeau, 1990; Lee et at., 1990; Zheng et
al., 1991; Dodson et al., 1993). The two most detailed reports
of LOH have concentrated on the terminal region of 6q. In a
study of 29 tumours, Foulkes et al. (1993) reported very high
frequencies (59-73%) of LOH at five loci in 6q27. Saito et
al. (1992a) allelotyped 70 tumours at nine loci spanning
6q24-q27 and identified in eight serous tumours a region of
common deletion flanked by D6S193 and D6S149 which are
separated genetically by 1.9 cM.
A second region of deletion spanning 6ql2-q23 was sug-
gested by Cliby et al. (1993). We have sought to define this
region more precisely by performing a study of the allelo-
types of coded blood-tumour DNAs from 40 patients with
ovarian tumours using highly polymorphic dinucleotide
repeat microsatellites. The study provides preliminary evi-
dence of the involvement of 6ql3-q23 in benign and endo-
metrioid tumours and also confirms the involvement of the
distal region in serous tumours.
Materials and methods
Patients and tissues
The study samples comprised 40 tumours classified as ten
benign, three borderline mucinous cystadenocarcinomas, four
mucinous carcinomas, 12 serous carcinomas and 11 endome-
trioid carcinomas. Tumours were staged according to the
FIGO (1971) classification, and tumour-rich areas were
dissected from surgically resected material and stored for
DNA extraction by snap freezing in liquid nitrogen. High
molecular weight DNA was prepared from tumour and peri-
pheral blood samples from each of the 40 patients by the
sodium dodecylsulphate (SDS)-proteinase K and phenol-
chloroform method (Sambrook et al., 1989). Samples were
coded in Belfast and sent to Manchester for analysis.
Analysis ofalleles
Two markers (D6S355 and D6S359) were isolated and char-
acterised in our laboratory (Orphanos et al., 1993, 1994a)
and seven markers (D6S280, D6S275, D6S284, D6S286,
D6S287, D6S300 and D6S313) were genetically mapped by
others (Weissenbach et al., 1992). Primers, polymerase chain
reaction (PCR) conditions and physical mapping of these loci
have been reported by Orphanos et al. (1994) and Menasce
et al. (1994a,b) and are shown in Figure 1. (CA). microsatel-
lites for D6S186 and D6S193, at 6q26 and 6q27 respectively
(Saito et al., 1992b), were isolated from cosmids generously
provided by Dr Y Nakamura using the method of Santi-
banez-Koref et al. (1993). The primers, annealing tempera-
tures and product sizes of these markers were reported
recently (Orphanos et al., 1995).
Polymerase chain reactions and the analysis of alleles by
phosphoimager have been described (Orphanos et al., 1993,
1995).
Results
Allelotyping of 12 dinucleotide microsatellites of chromo-
some 6q was performed on a coded series of blood and
tumour DNAs from 40 patients with ovarian tumours. The
frequency of heterozygosity observed in these patients varied
with the microsatellite used from 51% to 78%. After decod-
ing, we assessed the allelic imbalance (Al) at each locus in
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Figure 1 Localisation ofmicrosatellites. Vertical lines next to the
ideogram of chromosome 6q indicate the physical localisation of
the microsatellite loci used in this study, as determined by dele-
tion mapping with translocation hybrids.
individual patients shown by tumours of different histological
types and staging (Figure 2).
Of ten benign tumours, five had no AI and five had Al at
1-3 loci. The most frequent site ofimbalance was D6S287 at
6q21-q22.3, which was observed in four of seven samples
(57%).
The pattern of AI in three borderline mucinous cystadeno-
carcinomas was specific to the particular tumour: tumour 29
showed no imbalance, tumour 11 showed imbalance at a
single locus (D6S275) and tumour 20 showed imbalance at
four loci in two separate regions.
No Al was observed in the four mucinous tumours ana-
lysed.
In serous tumours, extensive imbalance involving more
than three loci was observed in five tumours (5, 27, 40, 42,
44) of FIGO stage III. However, we also observed no im-
balance in another three tumours (14, 15, 41) from patients
with stage III disease. The region showing highest imbalance
in serous tumours was at 6q26-q27, where imbalance at
D6S186 was observed in 5/8 informative patients (62%), and
at D6S193, where 6/8 informative patients (75%) showed
imbalance: Al occurred at one or other of these loci in 7/10
informative patients.
Endometrioid tumours, in contrast, showed AI frequencies
at D6S186 and D6S193 of 2/7 and 2/9 informative cases
respectively, a combined frequency of 3/11 that was con-
siderably less than that of the serous tumours. However,
endometrioid tumours showed high frequencies of Al at
D6S287 (5/8 = 62%), the locus involved in some benign
tumours, and at D6S284 (5/7 = 71%) located at 6q14-q15.
Discussion
We measured allelic imbalance at 12 loci on chromosome 6q
in a coded panel of 40 blood-tumour pairs from 40 patients
with ovarian cancer. Since Al has been shown to result
predominantly from allele loss (Devilee et al., 1991), the
667
Figure 2 Allelic imbalance of chromosome 6q in tumours from
individual patients. Minus signs indicate homozygosity at a locus:
open circles indicate heterozygosity with no Al in the tumour:
closed circles indicate heterozygosity with Al in the tumour:
blank cells, not determined. Tumours were classified as benign,
borderline mucinous cystadenocarcinoma (BMCA), mucinous
(M), serous (S) and endometrioid (E). FIGO stages I-IV are
indicated. Regions that maximise the possible extent of Al are
outlined in heavy boxes.
results can be interpreted in terms of allele loss at sites close
to tumour-suppressor genes (Osborne and Leech, 1994).
Interpretation is also dependent on the accurate ordering
of loci. The order shown in Figure 1 is in accord with the
consensus map that resulted from the Second International
Chromosome 6 Workshop (Volz et al., 1994). We are uncer-
tain of the order of D6S359 and D6S287, but we have placed
D6S359 distal to D6S287 in 6q21-q23.3 because this mini-
mises the number of deletion breakpoints in the tumour
samples, e.g. patient 18 shows Al of D6S300 and D6S287,
which could represent their loss in one event if these loci are
adjacent, but two events would be required if they are
separated by D6S359. A similar argument applies to patient
1. Also, we are uncertain of the order of D6S193 and
D6S297 in 6q27. Minimising the breakpoints in the infor-
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Table I Summary of Al in ovarian tumours according to tumour type
q23.3-
q13 q14-15 ql6.3-21 q21-23.3 25.2 q26 q27
313 280 284 286 275 300 287 359 355 186 193 297
Benign 0/6 0/8 0/6 2/9 1/5 2/7 4/7 0/5 0/7 1/5 0/6 0/5
(10 samples) 0 0 0 22 20 29 57 0 0 20 0 0
Borderline 0/2 0/3 1/3 1/2 2/3 0/2 0/1 0/2 0/1 0/2 1/2
(three samples) 0 0 33 50 67 0 0 0 0 0 50
Mucinous 0/1 0/3 0/3 0/2 0/2 0/2 0/2 0/2 0/2 0/1 0/4 0/1
(four samples) 0 0 0 0 0 0 0 0 0 0 0 0
Serous 2/7 3/7 2/10 4/10 2/6 3/6 1/5 2/6 1/3 5/8 6/8 1/4
(12 samples) 29 43 20 40 33 50 20 33 33 62 75 25
Endometrioid 1/6 2/4 5/7 3/7 2/7 3/6 5/8 0/5 1/5 2/7 2/9 1/5
(11 samples) 17 50 71 43 29 50 62 0 20 29 22 20
Total 3/22 5/25 8/29 10/30 7/23 8/23 10/23 2/20 2/17 8/22 8/29 3/17
(40 samples) 14 20 28 33 30 34 43 10 12 36 28 18
Ratios are number of tumours showing Al over number of informative patients; lower numbers are percentages. Four regions of high Al are
highlighted in bold type (see text).
mative patients (numbers 20, 40, 38) places D6S297 distal to
D6S193.
When the data for all patients are considered (Table I), the
frequency of Al is seen to vary from 10% to 43% between
loci, with D6S287 appearing as the most frequently involved
locus (43%). However, when classified according to histo-
logical type, the results appear more informative. Only the
group of four mucinous tumours failed to show AI, in agree-
ment with previous molecular observations (Saito et al.,
1992a; Foulkes et al., 1993) and the cytogenetic observation
that most well-differentiated mucinous tumours have normal
karyotypes (Pejovic et al., 1992).
With serous tumours the highest Al was observed at
6q26-q27 with D6S186 and D6S193, which together showed
70% AI. These observations support the findings of Saito et
al. (1992a) that imbalance occurs at high frequency close to
D6S193. We did not test D6S149 (the other flanking RFLP
used by Saito et al., 1992a) in this study because we were
unable to isolate a dinucleotide repeat sequence from cos-
mid cC16-24. Although Al was often very extensive in stage
II and IV serous tumours, four tumours (14, 15, 41 and 38)
showed no Al. This suggests that deletions of chromosome
6q are not obligatory in the progression of serous tumours,
although, of course, deletions may be present at loci we
have not examined. With the application of an increasing
density of markers it is likely that the frequency of inter-
stitial deletions, already high, may increase owing to the
detection of random events. Our data also show evidence
for the involvement of proximal 6q, possibly at three dis-
tinct regions: in early-stage tumours at D6S275-D6S300 and
in endometrioid tumours around D6S287 and also at
D6S284.
Early-stage tumours from patients 18 (benign), 11 (border-
line) and 13 (serous stage I) had minor regions of AI that
suggested a smallest region of deletion between D6S275 and
D6S300 (0.9cM; Volz et al., 1994). Of the tumours that
showed AI at any locus, this region may be involved in 3/5
benign tumours, 3/3 borderline tumours, 7/10 serous tumours
and 5/9 endometrioid tumours.
The involvement of D6S287 (6q21-q22.3) in all four
benign tumours and in 6/9 endometrioid tumours that
showed Al at any locus suggests that this region may be
involved early in the progression of endometrioid tumours.
Imbalance at D6S284 (6ql4-ql5) also occurred at high fre-
quency (71%) in endometrioid tumours, but at low frequen-
cies in borderline and serous tumours (33% and 20% respec-
tively) and not at all in benign tumours. The distance
between D6S287 and D6S284 is large (at least 10.9 cM, the
separation of Genethon marker D6S300, closest to D6S287,
and D6S284; Volz et al., 1994); however, because of the small
sample sizes of these subgroups, we cannot be certain that
the results indicate the presence of separate putative tumour
suppressors within this region.
The presence of a tumour suppressor(s) in the proximal
half of 6q was also suggested by other recent studies from
our laboratory. Deletion of a region containing D6S246 at
6ql6.3 was demonstrated by fluorescence in situ hybridisation
in one of two chromosome 6 homologues in blood lympho-
cytes from patients with acute lymphocytic leukaemia (ALL)
(Menasce et al., 1994b) and non-Hodgkin's lymphoma
(NHL) (Menasce et al., 1994a) patients previously diagnosed
as having del (6q). A study of AI in breast tumours
(Orphanos et al., 1995) yielded results similar to that
obtained here, i.e. the involvement of a large part of prox-
imal 6q and of 6q26-q27. As in the present group of endo-
metrioid tumours, the proximal 6q region appears relatively
more important in malignant breast tumours than the distal
region.
In conclusion, the results of this study provide preliminary
evidence which needs to be confirmed with a larger cohort of
samples, for the involvement of at least two regions of
chromosome 6q in the progression of different histological
types of tumour. Only mucinous tumours appear not to have
6q involvement.
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